San Francisco, California, July 28, 2017: Malignant pleural effusion is a condition when fluid get amassed between pleural tissues and chest wall. This condition occurs due to various types of cancers specially lung cancer and breast cancer. Despite of these cancers, lymphoma and pleural mesothelioma too are major causes of this illness. Common symptoms experienced include impotency to do labor work, dry cough, chest pain, breath contraction, etc. Elementary physical examination and x-ray can detect this state of sickness and is verified by thoracentesis process and ultrasound imaging.
The rising cancer occurrences are demanding the malignant pleural effusion market to grow exponentially. TMR Research provides a report that estimates this market to rise with an impressive CAGR during 2017–2025.
Patients suffering with malignant pleural effusion have to spend most of their earning on the treatment for a significant time period. Realizing the needs of patients, many companies and research institutes have started researching and developing innovative ways that could be cheaper and more beneficial for patients. This is a prominent driving factor for this industry.
A U.S. based National Cancer Institute has collaborated with University of Virginia to study role of docetaxel in treating malignant pleural effusion patients. Whereas, China-based Jiangsu Simcere Pharmaceutical Company, Ltd. is researching on applications of cisplatin and endostar.
Similarly, Prestigious University has collaborated with Advantagene, Inc. to develop intrapleural “AdV-tk” therapy, Chinese National Taiwan University Hospital is working on intrapleural “bevacizumab” injection, and a Swiss-based multinational pharmaceutical company, Novartis Pharmaceuticals is evaluating the effects of “zometa” as adjuvant treatment of malignant pleural effusion that is caused due to non-small cell lung cancer.
Whereas the high costs of treatment may act as a restraining factor for this industry, various programs initiated by governments of many nations to fight this fatal illness are estimated to aid a significant progress in the development of this industry.
Geographically segmented into Asia Pacific, Europe, North America, and rest of the world, this report gives an overview of the market in respective regions with the regional driving factors. The U.K. has a prominent market in Europe accounting for 50%-65% of the market. Whereas, the U.S., has a significant market in North America. In 2009, according to a journal by American Thoracic Society, over 200,000 new incidences of malignant pleural effusion are reported every year in the U.S.
This report by TMR Research evaluates the various segments of the malignant pleural effusion market and compares all the geographical segments.
Furthermore, this report consists of growth opportunities for established as well as the emerging markets. Key business strategies followed by prominent market players, recent and future trends and restrains, and detailed analysis of key segments of the malignant pleural effusion market are also included.